ArticleScientific reports2026
Synthesis, characterization, DFT and in silico anti-ulcer activities of novel sulphonamide derivatives.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptic ulcer disease (PUD) is a major gastrointestinal disorder associated with Helicobacter pylori infection and long-term use of non-steroidal anti-inflammatory drugs (NSAIDs). Current treatment strategies face limitations due to drug resistance, recurrence, and adverse effects, highlighting the need for novel therapeutic scaffolds. In this study, four newly designed sulfonamide derivatives (CPD-1 to CPD-4) were synthesized, characterized using state-of-the art instruments, and evaluated for anti-ulcer activities through a comprehensive computational chemistry approach. Density functional theory (DFT) optimizations with B3LYP, ωB97XD, and M06-2X functionals confirmed molecular stability and reactivity. Frontier molecular orbital (FMO) analysis revealed small HOMO–LUMO gaps, with CPD-1 exhibiting the lowest energy (3.71 eV), suggesting high chemical reactivity. Natural bond orbital (NBO) analysis indicated strong intramolecular charge transfer and stabilization, while molecular electrostatic potential (MESP) maps identified regions favorable for electrophilic and nucleophilic interactions. Non-covalent interaction (NCI) plots further supported stabilization through hydrogen bonding and van der Waals interactions. Docking studies against H. pylori CagI protein (PDB ID: 8AK1) showed CPD-1 had the strongest binding affinity (− 7.2 kcal/mol), stabilized by five hydrogen bonds, surpassing the reference drug DB00338. ADMET predictions revealed that CPD-2 had the most favorable pharmacokinetic and safety profile, with acceptable clearance, moderate plasma protein binding, and compliance with Lipinski’s rules. Collectively, these results suggest that CPD-1, CPD-2, and CPD-3 are promising candidates for further development as anti-ulcer agents. This integrative approach demonstrates the power of combining DFT, docking, and ADMET modeling for the rational design of novel therapeutics targeting H. pylori.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.